Cardiff Oncology Inc (CRDF)

$1.39

-0.04

(-2.8%)▲

Market is closed - opens 7 PM, 02 Oct 2023

Insights on Cardiff Oncology Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 83.0K → 108.0K (in $), with an average increase of 23.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -11.22M → -11.15M (in $), with an average increase of 0.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 82.6% return, outperforming this stock by 92.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 162.0% return, outperforming this stock by 252.2%

Performance

  • $1.31
    $1.41
    $1.39
    downward going graph

    5.76%

    Downside

    Day's Volatility :7.09%

    Upside

    1.42%

    downward going graph
  • $1.20
    $2.79
    $1.39
    downward going graph

    13.67%

    Downside

    52 Weeks Volatility :56.99%

    Upside

    50.18%

    downward going graph

Returns

PeriodCardiff Oncology IncSector (Health Care)Index (Russel 2000)
3 Months
-5.44%
-3.0%
0.0%
6 Months
-15.76%
0.5%
0.0%
1 Year
-9.74%
6.3%
6.3%
3 Years
-90.2%
22.1%
17.3%

Highlights

Market Capitalization
82.7M
Book Value
$1.94
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.88
Wall Street Target Price
7.33
Profit Margin
0.0%
Operating Margin TTM
-10350.73%
Return On Assets TTM
-23.31%
Return On Equity TTM
-38.29%
Revenue TTM
412.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
18.7%
Gross Profit TTM
-26.7M
EBITDA
-42.3M
Diluted Eps TTM
-0.88
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.06
EPS Estimate Next Year
-1.29
EPS Estimate Current Quarter
-0.26
EPS Estimate Next Quarter
-0.27

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Cardiff Oncology Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 427.34%

Current $1.39
Target $7.33

Company Financials

FY17Y/Y Change
Revenue
505.4K
↑ 32.63%
Net Income
-24.9M
↓ 36.47%
Net Profit Margin
-4.9K%
↑ 5359.66%
FY18Y/Y Change
Revenue
378.3K
↓ 25.14%
Net Income
-16.5M
↓ 33.91%
Net Profit Margin
-4.4K%
↑ 577.02%
FY19Y/Y Change
Revenue
244.6K
↓ 35.34%
Net Income
-16.4M
↓ 0.29%
Net Profit Margin
-6.7K%
↓ 2358.67%
FY20Y/Y Change
Revenue
366.0K
↑ 49.61%
Net Income
-19.3M
↑ 17.62%
Net Profit Margin
-5.3K%
↑ 1434.59%
FY21Y/Y Change
Revenue
359.0K
↓ 1.91%
Net Income
-28.3M
↑ 46.53%
Net Profit Margin
-7.9K%
↓ 2605.35%
FY22Y/Y Change
Revenue
386.0K
↑ 7.52%
Net Income
-38.7M
↑ 36.89%
Net Profit Margin
-10.0K%
↓ 2152.66%
Q1 FY22Q/Q Change
Revenue
74.0K
↓ 44.36%
Net Income
-11.0M
↑ 16.43%
Net Profit Margin
-14.9K%
↓ 7756.16%
Q2 FY22Q/Q Change
Revenue
91.0K
↑ 22.97%
Net Income
-10.4M
↓ 5.0%
Net Profit Margin
-11.5K%
↑ 3379.59%
Q3 FY22Q/Q Change
Revenue
93.0K
↑ 2.2%
Net Income
-8.6M
↓ 17.93%
Net Profit Margin
-9.2K%
↑ 2259.69%
Q1 FY23Q/Q Change
Revenue
83.0K
-
Net Income
-11.2M
↑ 28.69%
Net Profit Margin
-13.5K%
-
Q2 FY23Q/Q Change
Revenue
108.0K
↑ 30.12%
Net Income
-11.2M
↓ 0.6%
Net Profit Margin
-10.3K%
↑ 3192.06%
FY17Y/Y Change
Total Assets
12.3M
↓ 72.05%
Total Liabilities
5.8M
↓ 76.1%
FY18Y/Y Change
Total Assets
14.2M
↑ 15.36%
Total Liabilities
4.1M
↓ 29.25%
FY19Y/Y Change
Total Assets
13.1M
↓ 7.66%
Total Liabilities
5.8M
↑ 41.26%
FY20Y/Y Change
Total Assets
134.7M
↑ 929.51%
Total Liabilities
6.6M
↑ 13.75%
FY21Y/Y Change
Total Assets
149.5M
↑ 11.0%
Total Liabilities
9.1M
↑ 38.93%
FY22Y/Y Change
Total Assets
116.2M
↓ 22.3%
Total Liabilities
9.8M
↑ 7.9%
Q1 FY22Q/Q Change
Total Assets
139.2M
↓ 6.91%
Total Liabilities
9.1M
↓ 0.27%
Q2 FY22Q/Q Change
Total Assets
131.3M
↓ 5.71%
Total Liabilities
10.8M
↑ 18.51%
Q3 FY22Q/Q Change
Total Assets
123.6M
↓ 5.81%
Total Liabilities
10.4M
↓ 3.41%
Q4 FY22Q/Q Change
Total Assets
116.2M
↓ 6.02%
Total Liabilities
9.8M
↓ 5.48%
Q1 FY23Q/Q Change
Total Assets
106.5M
↓ 8.3%
Total Liabilities
10.0M
↑ 2.01%
Q2 FY23Q/Q Change
Total Assets
97.5M
↓ 8.54%
Total Liabilities
10.9M
↑ 8.26%
FY17Y/Y Change
Operating Cash Flow
-23.3M
↓ 25.0%
Investing Cash Flow
24.0M
↓ 196.49%
Financing Cash Flow
-6.4M
↓ 377.14%
FY18Y/Y Change
Operating Cash Flow
-13.2M
↓ 43.31%
Investing Cash Flow
22.8K
↓ 99.9%
Financing Cash Flow
16.4M
↓ 357.19%
FY19Y/Y Change
Operating Cash Flow
-13.3M
↑ 0.52%
Investing Cash Flow
-67.6K
↓ 396.04%
Financing Cash Flow
12.1M
↓ 26.37%
FY20Y/Y Change
Operating Cash Flow
-16.3M
↑ 22.97%
Investing Cash Flow
-211.9K
↑ 213.33%
Financing Cash Flow
137.3M
↑ 1036.95%
FY21Y/Y Change
Operating Cash Flow
-23.0M
↑ 41.22%
Investing Cash Flow
-131.4M
↑ 61938.89%
Financing Cash Flow
35.5M
↓ 74.18%
FY22Y/Y Change
Operating Cash Flow
-33.8M
↑ 46.79%
Investing Cash Flow
38.1M
↓ 129.02%
Financing Cash Flow
75.0K
↓ 99.79%
Q1 FY22Q/Q Change
Operating Cash Flow
-10.2M
↑ 38.69%
Investing Cash Flow
18.4M
↓ 308.76%
Financing Cash Flow
75.0K
↓ 99.5%
Q2 FY22Q/Q Change
Operating Cash Flow
-6.7M
↓ 34.68%
Investing Cash Flow
7.6M
↓ 58.56%
Financing Cash Flow
75.0K
↑ 0.0%
Q3 FY22Q/Q Change
Operating Cash Flow
-7.5M
↑ 11.81%
Investing Cash Flow
5.2M
↓ 32.14%
Financing Cash Flow
75.0K
↑ 0.0%

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cardiff Oncology Inc
Cardiff Oncology Inc
-22.35%
-15.76%
-9.74%
-90.2%
-71.04%
Moderna, Inc.
Moderna, Inc.
-11.43%
-29.94%
-12.65%
45.99%
455.32%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.44%
1.41%
19.47%
47.01%
108.75%
Novo Nordisk A/s
Novo Nordisk A/s
-3.29%
15.05%
82.56%
161.96%
290.64%
Seagen, Inc.
Seagen, Inc.
2.56%
4.47%
55.05%
8.41%
161.4%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.86%
11.4%
20.1%
27.79%
81.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cardiff Oncology Inc
Cardiff Oncology Inc
NA
NA
NA
-1.06
-0.38
-0.23
0.0
1.94
Moderna, Inc.
Moderna, Inc.
34.94
34.94
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.08
22.08
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.05
43.05
2.03
1.64
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.67
26.67
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cardiff Oncology Inc
Cardiff Oncology Inc
Buy
$82.7M
-71.04%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.2B
455.32%
34.94
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.6B
108.75%
22.08
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$412.6B
290.64%
43.05
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$39.8B
161.4%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$89.7B
81.52%
26.67
35.4%

Institutional Holdings

  • Vanguard Group Inc

    4.35%

  • BlackRock Inc

    1.70%

  • LAURION CAPITAL MANAGEMENT LP

    1.62%

  • Geode Capital Management, LLC

    0.85%

  • Renaissance Technologies Corp

    0.70%

  • GSA Capital Partners LLP

    0.66%

Corporate Announcements

  • Cardiff Oncology Inc Earnings

    Cardiff Oncology Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary precision cancer monitoring® (pcm) technology in tumor genomics. trovagene has broad intellectual property and proprietary technology to measure circulating tumor dna (ctdna) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. trovagene offers its pcm technology at its clia/cap – accredited laboratory and plans to continue to vertically integrate its pcm technology with precision cancer therapeutics. trovagene's lead therapeutic asset is pcm-075, an oral, investigational drug and a highly-selective polo-like kinase 1 (plk1) inhibitor for the treatment of acute myeloid leukemia (aml). among the four members of the plk family, plk1 is recognized to be the fundamental component for cell division to take place correctly. most importantly, plk1 is only expressed in dividing cells, wh

Organization
Cardiff Oncology Inc
Employees
25
CEO
Dr. Mark Erlander Ph.D.
Industry
Health Services

Discover More

FAQs